---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053304"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2026-08-05T20:04:27+00:00"
generated_at: "2026-08-05T20:05:05.701396+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vistagen gets Nasdaq extension to Feb 1, 2027 to cure $1.00 bid price deficiency

## Summary
- Received 180-day extension until February 1, 2027 to regain compliance with Nasdaq minimum bid price of $1.00.
- Previously disclosed non-compliance on February 6, 2026; has not yet cured the deficiency.
- If not compliant by end of Extension Period, Nasdaq will issue delisting notice; company may appeal.
- No assurance that any appeal of a delisting determination would be successful.

## SEC filing metadata
- accession: 0001628280-26-053304
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2026-08-05T20:04:27+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/0001628280-26-053304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828026053304/vtgn-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053304
- JSON: https://secwatch.observer/filing/0001628280-26-053304.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.